19 completed, 8 terminated, 7 recruiting, 5 active not recruiting. 27 Phase 2, 6 Phase 1, 2 Early Phase 1, 1 Not applicable, 1 Phase 3.
Follow Secondary Myelofibrosis: new trials by email Literature Review of Secondary Myelofibrosis trials Research Report on Secondary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Research Platform Myelofibrosis and Anemia Primary Myelofibrosis, Secondary Myelofibrosis | Recruiting | iOMEDICO AG | 200 | 2026-02-19 | 2026-06-05 | |
| Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes Ruxolitinib, Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan - Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-02-04 | 2026-10-19 |
| MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) Polycythemia Vera, ET (Essential Thrombocythemia) | Recruiting | MPN Research Foundation | 5000 | 2025-09-26 | 2026-01-23 | |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 78 | 2025-08-14 | 2026-09-30 |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Cyclophosphamide, Itacitinib, Peripheral Blood Stem Cell Transplantation - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | City of Hope Medical Center | 20 | 2022-12-29 | 2026-10-14 |
| Fedratinib in Combination With Nivolumab Fedratinib Oral Capsule [Inrebic], Nivolumab - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 30 | 2022-06-14 | 2026-04-08 |
| Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera Myelofibrosis, Primary Myelofibrosis | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1055 | 2022-05-06 | 2024-12-05 | |
| Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis Cyclophosphamide, JAK Inhibitor, Fludarabine - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 20 | 2021-02-09 | 2026-07-20 |
| Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2020-12-18 | 2026-04-14 |
| Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation Fludarabine, Itacitinib Adipate, Melphalan - Acute Leukemia, Hematologic and Lymphocytic Disorder | Phase 2 | Completed | City of Hope Medical Center | 59 | 2020-11-11 | 2026-03-30 |
| Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms Decitabine, Ruxolitinib, Fedratinib - Acute Myeloid Leukemia, Essential Thrombocythemia | Phase 2 | Recruiting | University of Washington | 25 | 2020-03-24 | 2026-09-17 |
| Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis Busulfan, Cyclophosphamide, Fludarabine - Anemia, ASXL1 Gene Mutation | Phase 2 | Terminated | University of Utah | 6 | 2018-03-30 | 2022-05-05 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Primary Myelofibrosis, Secondary Myelofibrosis | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 3 | 2018-01-31 | 2020-10-14 |
| Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine - Secondary Myelofibrosis | Phase 1 | Active not recruiting | City of Hope Medical Center | 22 | 2017-06-21 | 2026-08-21 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Platelet Transfusion - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 4 | 2017-06-09 | 2019-10-21 |
| Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine, Fludarabine Phosphate - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 1 | Completed | City of Hope Medical Center | 18 | 2016-11-13 | 2023-12-12 |
| Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate - Acute Myeloid Leukemia in Remission, Primary Myelofibrosis | Phase 1 | Withdrawn | City of Hope Medical Center | 2015-11-01 | 2016-09-14 | |
| P1101 in Treating Patients With Myelofibrosis Laboratory Biomarker Analysis, Quality-of-Life Assessment, Ropeginterferon Alfa-2B - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Terminated | Mayo Clinic | 11 | 2015-08-12 | 2025-10-27 |
| LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis Laboratory Biomarker Analysis, Questionnaire Administration, Smac Mimetic LCL161 - Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis | Phase 2 | Completed | M.D. Anderson Cancer Center | 50 | 2014-12-18 | 2023-06-06 |
| JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Primary Myelofibrosis, Secondary Myelofibrosis | Phase 2 | Completed | Fred Hutchinson Cancer Center | 61 | 2014-10-20 | 2026-03-30 |
Showing 20 of 41. Sign in to see all of them.
Primary Myelofibrosis (36) · Myeloproliferative Disorders (19) · Leukemia, Myeloid, Acute (12) · Myelodysplastic Syndromes (12) · Polycythemia Vera (12) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Leukemia, Lymphocytic, Chronic, B-Cell (11) · Burkitt Lymphoma (10) · Congenital Abnormalities (10) · Lymphoma, B-Cell, Marginal Zone (10) · Lymphoma, Follicular (10) · Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Large-Cell, Immunoblastic (10) · Lymphoma, Mantle-Cell (10) · Multiple Myeloma (10)
Bone Marrow Diseases (40) · Hemic and Lymphatic Diseases (40) · Hematologic Diseases (38) · Neoplasms (23) · Myeloproliferative Disorders (21) · Hemorrhagic Disorders (20) · Neoplasms by Histologic Type (17) · Leukemia, Myeloid (15) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Cardiovascular Diseases (13) · Chronic Disease (13) · Disease Attributes (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13)
Tacrolimus (15) · Cyclophosphamide (14) · Melphalan (11) · Mycophenolic Acid (10) · Whole-Body Irradiation (10) · Peripheral Blood Stem Cell Transplantation (9) · Busulfan (8) · fludarabine phosphate (8) · ruxolitinib (8) · fludarabine (7) · Methotrexate (6) · Stem Cell Transplantation (5) · merphos (5) · Flow Cytometry (4) · Sirolimus (4)
City of Hope Medical Center (7) · Fred Hutchinson Cancer Center (6) · Mayo Clinic (6) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · University of Utah (2) · Barbara Ann Karmanos Cancer Institute (1) · Case Comprehensive Cancer Center (1) · Geron Corporation (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · MPN Research Foundation (1) · Masonic Cancer Center, University of Minnesota (1) · Northwestern University (1) · Roswell Park Cancer Institute (1)
United States (36) · Germany (3) · Australia (1) · Canada (1) · Italy (1) · New Zealand (1) · Saudi Arabia (1)
Ruben A. Mesa, MD (4) · Haris Ali (3) · Rachel B. Salit (3) · Monzr M Al Malki (2) · Anand A Patel (1) · Andrew Rezvani (1) · Anna Halpern (1) · Ayalew Tefferi, MD (1) · Brenda Cooper, MD (1) · Brian J. Bolwell, MD (1) · Catherine Lee, MD (1) · Claudio G. Brunstein, MD, PhD (1) · David Garcia (1) · George Chen (1) · Jarek Maciejewski, MD, PhD (1)
PMID 26332545, PMID 28935847, PMID 34424319, PMID 34581764, PMID 38967662, PMID 39250708
P30CA015083 (5), P30CA033572 (3), P30CA015704 (2), N01CM62201 (1), N01CM62207 (1), P01CA108671 (1), P01HL036444 (1), P30CA014599 (1), P30CA016672 (1), P30CA022453 (1), P30CA036727 (1), P30CA043703 (1), UM1CA186717 (1)